GB1560788A - Antigen from neopalsm its antibody and methods for their production and use - Google Patents
Antigen from neopalsm its antibody and methods for their production and use Download PDFInfo
- Publication number
- GB1560788A GB1560788A GB36459/76A GB3645976A GB1560788A GB 1560788 A GB1560788 A GB 1560788A GB 36459/76 A GB36459/76 A GB 36459/76A GB 3645976 A GB3645976 A GB 3645976A GB 1560788 A GB1560788 A GB 1560788A
- Authority
- GB
- United Kingdom
- Prior art keywords
- nea
- antibody
- antigen
- solution
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 124
- 239000000427 antigen Substances 0.000 title claims description 59
- 102000036639 antigens Human genes 0.000 title claims description 59
- 108091007433 antigens Proteins 0.000 title claims description 59
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 241000769223 Thenea Species 0.000 claims description 145
- 239000000243 solution Substances 0.000 claims description 108
- 206010028980 Neoplasm Diseases 0.000 claims description 82
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 62
- 102000004169 proteins and genes Human genes 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 239000007853 buffer solution Substances 0.000 claims description 43
- 239000003153 chemical reaction reagent Substances 0.000 claims description 29
- 239000000499 gel Substances 0.000 claims description 25
- 210000003743 erythrocyte Anatomy 0.000 claims description 23
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 20
- 239000002244 precipitate Substances 0.000 claims description 20
- 241001494479 Pecora Species 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 19
- 239000002609 medium Substances 0.000 claims description 18
- 238000001962 electrophoresis Methods 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 238000000760 immunoelectrophoresis Methods 0.000 claims description 16
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 13
- 229940027941 immunoglobulin g Drugs 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 238000003127 radioimmunoassay Methods 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 11
- 239000000523 sample Substances 0.000 claims description 11
- 238000001042 affinity chromatography Methods 0.000 claims description 10
- 230000000951 immunodiffusion Effects 0.000 claims description 9
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 claims description 8
- 238000002523 gelfiltration Methods 0.000 claims description 8
- 238000004440 column chromatography Methods 0.000 claims description 7
- 239000003957 anion exchange resin Substances 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- -1 alkali metal cyanate Chemical class 0.000 claims description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 5
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 5
- 229940098773 bovine serum albumin Drugs 0.000 claims description 5
- 229920000936 Agarose Polymers 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229960002319 barbital Drugs 0.000 claims description 4
- 230000035931 haemagglutination Effects 0.000 claims description 4
- 239000004816 latex Substances 0.000 claims description 4
- 229920000126 latex Polymers 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 3
- 235000010419 agar Nutrition 0.000 claims description 3
- 210000000601 blood cell Anatomy 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 241000206672 Gelidium Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000010748 Photoabsorption Effects 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 2
- 239000004800 polyvinyl chloride Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 description 104
- 239000002504 physiological saline solution Substances 0.000 description 46
- 239000000203 mixture Substances 0.000 description 31
- 238000012360 testing method Methods 0.000 description 29
- 229910019142 PO4 Inorganic materials 0.000 description 28
- 239000010452 phosphate Substances 0.000 description 28
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 28
- 239000006228 supernatant Substances 0.000 description 26
- 238000001514 detection method Methods 0.000 description 25
- 238000003745 diagnosis Methods 0.000 description 24
- 238000001556 precipitation Methods 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 21
- 239000008055 phosphate buffer solution Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 16
- 229920005654 Sephadex Polymers 0.000 description 15
- 239000012507 Sephadex™ Substances 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 206010003445 Ascites Diseases 0.000 description 12
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 11
- 238000002649 immunization Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 239000001263 FEMA 3042 Substances 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 229940033123 tannic acid Drugs 0.000 description 8
- 229920002258 tannic acid Polymers 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010016654 Fibrosis Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000007882 cirrhosis Effects 0.000 description 7
- 208000019425 cirrhosis of liver Diseases 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000021235 carbamoylation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 230000004520 agglutination Effects 0.000 description 5
- 230000003260 anti-sepsis Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 201000000498 stomach carcinoma Diseases 0.000 description 5
- 102000006395 Globulins Human genes 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 206010046766 uterine cancer Diseases 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 101000962041 Homo sapiens Neurobeachin Proteins 0.000 description 3
- 102100039234 Neurobeachin Human genes 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 206010033649 Pancreatitis chronic Diseases 0.000 description 3
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 241000473945 Theria <moth genus> Species 0.000 description 3
- 239000001166 ammonium sulphate Substances 0.000 description 3
- 239000007982 barbital buffer Substances 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 210000003022 colostrum Anatomy 0.000 description 3
- 235000021277 colostrum Nutrition 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 208000000718 duodenal ulcer Diseases 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 208000025036 lymphosarcoma Diseases 0.000 description 3
- 208000004396 mastitis Diseases 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 201000003068 rheumatic fever Diseases 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000005185 salting out Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 3
- 235000015523 tannic acid Nutrition 0.000 description 3
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010073069 Hepatic cancer Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000013066 combination product Substances 0.000 description 2
- 229940127555 combination product Drugs 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229940098197 human immunoglobulin g Drugs 0.000 description 2
- 229940099472 immunoglobulin a Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- HJBUBXIDMQBSQW-UHFFFAOYSA-N 4-(4-diazoniophenyl)benzenediazonium Chemical compound C1=CC([N+]#N)=CC=C1C1=CC=C([N+]#N)C=C1 HJBUBXIDMQBSQW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001214714 Niea Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- YXVJNOXXPKIWIM-UHFFFAOYSA-N n-(2-hydroxyethyl)-n-(2-hydroxypropyl)nitrous amide Chemical compound CC(O)CN(N=O)CCO YXVJNOXXPKIWIM-UHFFFAOYSA-N 0.000 description 1
- HVAAHUDGWQAAOJ-UHFFFAOYSA-N n-benzylethanamine Chemical compound CCNCC1=CC=CC=C1 HVAAHUDGWQAAOJ-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57476—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofetal proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10588275A JPS5949544B2 (ja) | 1975-09-03 | 1975-09-03 | 新生物診断用ｎｅａ抗体の製造方法 |
| JP10588375A JPS6049866B2 (ja) | 1975-09-03 | 1975-09-03 | Ｎｅａおよびｎｅａ抗体の精製法 |
| JP50107228A JPS6055779B2 (ja) | 1975-09-04 | 1975-09-04 | 新生物診断用試薬の製法 |
| JP10648575A JPS5241220A (en) | 1975-09-04 | 1975-09-04 | Method of manufacturing diagnostic agent for neoplasm |
| JP50106483A JPS6057021B2 (ja) | 1975-09-04 | 1975-09-04 | 新生物診断剤の製法 |
| JP50106484A JPS5241219A (en) | 1975-09-04 | 1975-09-04 | Purification of nea (neoplasm embryonic antigen) |
| JP6607176A JPS52151725A (en) | 1976-06-08 | 1976-06-08 | Diagnostic reagent for neoplasm |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1560788A true GB1560788A (en) | 1980-02-13 |
Family
ID=27565094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB36459/76A Expired GB1560788A (en) | 1975-09-03 | 1976-09-02 | Antigen from neopalsm its antibody and methods for their production and use |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4152410A (enrdf_load_stackoverflow) |
| CA (1) | CA1080124A (enrdf_load_stackoverflow) |
| CH (1) | CH627187A5 (enrdf_load_stackoverflow) |
| DE (1) | DE2639623A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2323147A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1560788A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2223021A (en) * | 1988-09-21 | 1990-03-28 | Glaverbel | Biochemical separation of material from a fluid medium |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2456224A1 (de) * | 1974-11-28 | 1976-08-12 | Karl Dr Med Theurer | Verwendung von nativen antikoerpern oder von antikoerper-fragmenten mit kovalent gebundenen oder konjugierten zytostatisch und/bzw. oder zytotoxisch wirkenden substanzen fuer die krebstherapie |
| GB1598811A (en) * | 1977-01-12 | 1981-09-23 | Hoffmann La Roche | Carcinoma-associated antigens |
| JPS548714A (en) * | 1977-06-16 | 1979-01-23 | Saikin Kagaku Kenkiyuushiyo Kk | Production of specific antiserum |
| US4232001A (en) * | 1978-09-22 | 1980-11-04 | University Patents, Inc. | Methods and materials for detection of estrophilin |
| US4241044A (en) * | 1978-12-28 | 1980-12-23 | Abbott Laboratories | Method of diagnosing cancer by detecting elevated anti-T antibody activity |
| US4315851A (en) * | 1978-12-29 | 1982-02-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition having antitumor activity |
| ES488747A0 (es) * | 1979-01-30 | 1981-02-16 | Otsuka Pharma Co Ltd | Metodo de analizar fluidos corporales. |
| CA1150301A (en) * | 1979-11-27 | 1983-07-19 | Michael J. Bull | Cyclopropane carboxylic acid ester derivatives |
| CA1166957A (en) * | 1980-05-08 | 1984-05-08 | Barry I. Bluestein | Immunoassay for oncofetal antigen carried by lymphocytes |
| CA1190853A (en) * | 1981-10-13 | 1985-07-23 | Roberto L. Ceriani | Method and compositions for carcinoma diagnosis |
| US4863853A (en) * | 1982-04-21 | 1989-09-05 | Bartos Patent Development And Holding Company Limited | Method of determining the diagnostic value of monitoring serum-CEA-levels in a carcinoma patient undergoing therapy |
| US4818709A (en) * | 1983-01-21 | 1989-04-04 | Primus Frederick J | CEA-family antigens, Anti-CEA antibodies and CEA immunoassay |
| DE3432714A1 (de) * | 1984-09-06 | 1986-04-24 | Behringwerke Ag, 3550 Marburg | Tumortherapeutikum und verfahren zu seiner herstellung |
| JPS60214737A (ja) * | 1984-04-06 | 1985-10-28 | Nippon Koutai Kenkyusho:Kk | 糖鎖関連抗原の製造法 |
| DE3444684A1 (de) * | 1984-12-07 | 1986-06-19 | Karl Prof. Dr.med. 7302 Ostfildern Theurer | Herstellung von konjugierten antigenen und dagegen gerichteten antikoerpern (immunglobulinen) zu therapeutischen und prophylaktischen zwecken bei tumoren |
| US5086476A (en) * | 1985-11-04 | 1992-02-04 | Cell Analysis Systems, Inc. | Method and apparatus for determining a proliferation index of a cell sample |
| US5109429A (en) * | 1985-11-04 | 1992-04-28 | Cell Analysis Systems,Inc. | Apparatus and method for analyses of biological specimens |
| US5134662A (en) * | 1985-11-04 | 1992-07-28 | Cell Analysis Systems, Inc. | Dual color camera microscope and methodology for cell staining and analysis |
| US4998284A (en) * | 1987-11-17 | 1991-03-05 | Cell Analysis Systems, Inc. | Dual color camera microscope and methodology for cell staining and analysis |
| US4997537A (en) * | 1986-10-21 | 1991-03-05 | Northeastern University | High performance microcapillary gel electrophoresis |
| US5665216A (en) * | 1986-10-21 | 1997-09-09 | Northeastern University | Capillary column for high performance electrophoretic separation and detection of SDS proteins and system and using the same |
| US5179000A (en) * | 1987-07-24 | 1993-01-12 | Nippon Kayaku Kabushiki Kaisha | Method for assaying basic fetoprotein in urine and assay kit therefor |
| US4917878A (en) * | 1988-05-02 | 1990-04-17 | Thomas Jefferson University | Novel use of a radiolabelled antibody against stage specific embryonic antigen for the detection of occult abscesses in mammals |
| US20050277204A1 (en) * | 2003-08-12 | 2005-12-15 | Massachusetts Institute Of Technology | Sample preparation methods and devices |
| CN1882697A (zh) * | 2003-08-12 | 2006-12-20 | 麻省理工学院 | 样品制备方法和装置 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3867363A (en) * | 1970-06-01 | 1975-02-18 | Hans John Hansen | Carcinoembryonic antigens |
| US3697638A (en) * | 1970-06-01 | 1972-10-10 | Hoffmann La Roche | Antigens |
| US3663684A (en) * | 1970-06-01 | 1972-05-16 | Hoffmann La Roche | Carcinoembryonic antigen and diagnostic method using radioactive iodine |
| US3960827A (en) * | 1972-07-10 | 1976-06-01 | Bjoerklund K B | Cancer associated polypeptide antigen, process for its preparation, process for preparing antibodies, process of cancer diagnosis and composition useful as an immunizing agent |
| ZA723264B (en) * | 1972-10-13 | 1974-08-28 | H Van Til | Improvements in toys |
| US3927193A (en) * | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
-
1976
- 1976-09-01 US US05/719,505 patent/US4152410A/en not_active Expired - Lifetime
- 1976-09-02 GB GB36459/76A patent/GB1560788A/en not_active Expired
- 1976-09-02 DE DE19762639623 patent/DE2639623A1/de not_active Withdrawn
- 1976-09-02 CH CH1116776A patent/CH627187A5/de not_active IP Right Cessation
- 1976-09-03 FR FR7626628A patent/FR2323147A1/fr active Granted
- 1976-09-03 CA CA260,559A patent/CA1080124A/en not_active Expired
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2223021A (en) * | 1988-09-21 | 1990-03-28 | Glaverbel | Biochemical separation of material from a fluid medium |
| US5045201A (en) * | 1988-09-21 | 1991-09-03 | Glaverbel | Glass microbeads for biochemical separation of material from a fluid medium |
| GB2223021B (en) * | 1988-09-21 | 1992-05-20 | Glaverbel | Biochemical separation of material from a fluid medium |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2323147B1 (enrdf_load_stackoverflow) | 1981-07-31 |
| FR2323147A1 (fr) | 1977-04-01 |
| CH627187A5 (enrdf_load_stackoverflow) | 1981-12-31 |
| US4152410A (en) | 1979-05-01 |
| CA1080124A (en) | 1980-06-24 |
| DE2639623A1 (de) | 1977-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4152410A (en) | Diagnosis reagent for neoplasm and method for diagnosis of neoplasm | |
| Tomasi et al. | The selective occurrence of γ 1 A globulins in certain body fluids | |
| US4446122A (en) | Purified human prostate antigen | |
| JP2617289B2 (ja) | モノクローナル抗体生産性ハイブリドマ細胞系 | |
| USRE33405E (en) | Purified human prostate antigen | |
| US4489167A (en) | Methods and compositions for cancer detection | |
| US5512657A (en) | Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases | |
| FI61192B (fi) | Foerfarande foer framstaellning av ett saosom diagnostiskt medel anvaendbart vaevnadsprotein | |
| US4687734A (en) | Immunoassay for the detection of human colon cancer using a polyclonal antibody derived from a capillary culture of tumor cells | |
| US4645748A (en) | Protein which is characteristic of rheumatoid arthritis | |
| US3956258A (en) | Carcinoembryonic antigens | |
| US4746731A (en) | Isolated tissue protein PP18 | |
| JPS61282096A (ja) | 新規な腫瘍関連抗原 | |
| US4132767A (en) | Preparation of α-L antibody, purification of α-L antigen and reagent for detection of α-L antibody and α-L antigen | |
| US4325866A (en) | Protein, PP11, a process for its preparation and its use | |
| CA1165685A (en) | Purified prostatic tissue antigen | |
| EP0664453A1 (en) | Detection of basement membrane components as diagnostic of cancer and other diseases | |
| US4599318A (en) | Tissue protein PP19, a process for obtaining it, and its use | |
| EP0040020A2 (en) | Human reverse transcriptase enzyme, method for its purification, and its use in the detection of breast cancer | |
| EP0242727B1 (en) | Method of assaying adenocarcinoma antigens | |
| US3946105A (en) | Preparation of anti-α1-fetoglobulin | |
| Veltri et al. | A human tumour-associated membrane antigen from squamous-cell carcinoma of the lung | |
| JPS6284100A (ja) | 扁平上皮癌関連抗原に対する抗体及びその免疫学的利用法 | |
| JP3159744B2 (ja) | 抗腎抗体、それを含有する腎疾患診断薬、腎疾患診断キットおよび腎疾患由来抗原の測定法 | |
| JPS6055779B2 (ja) | 新生物診断用試薬の製法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| 732 | Registration of transactions, instruments or events in the register (sect. 32/1977) | ||
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19940902 |